TY - JOUR
T1 - Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups
AU - Soeda, Yoshiyuki
AU - Yoshikawa, Misato
AU - Almeida, Osborne F.X.
AU - Sumioka, Akio
AU - Maeda, Sumihiro
AU - Osada, Hiroyuki
AU - Kondoh, Yasumitsu
AU - Saito, Akiko
AU - Miyasaka, Tomohiro
AU - Kimura, Tetsuya
AU - Suzuki, Masaaki
AU - Koyama, Hiroko
AU - Yoshiike, Yuji
AU - Sugimoto, Hachiro
AU - Ihara, Yasuo
AU - Takashima, Akihiko
N1 - Funding Information:
This work was supported by JSPS KAKENHI Grant Number 23790313 (to Y.S.), Mext Grant-in-aid project, Scientific Research on Innovation Area (Brain Protein Aging and Dementia control (to A.T.), Brain environment (to A.T.)) and Strategic Research Program for Brain Science (‘Integrated Research on Neuropsychiatric Disorders’) from Japan Agency for Medical Research and development, AMED (to Y.I., A.T. and H.S.) and Intramural grant of NCGG (to A.T.).
PY - 2015/12/16
Y1 - 2015/12/16
N2 - Neurofibrillary tangles, composed of hyperphosphorylated tau fibrils, are a pathological hallmark of Alzheimers disease; the neurofibrillary tangle load correlates strongly with clinical progression of the disease. A growing body of evidence indicates that tau oligomer formation precedes the appearance of neurofibrillary tangles and contributes to neuronal loss. Here we show that tau oligomer formation can be inhibited by compounds whose chemical backbone includes 1,2-dihydroxybenzene. Specifically, we demonstrate that 1,2-dihydroxybenzene-containing compounds bind to and cap cysteine residues of tau and prevent its aggregation by hindering interactions between tau molecules. Further, we show that orally administered DL-isoproterenol, an adrenergic receptor agonist whose skeleton includes 1,2-dihydroxybenzene and which penetrates the brain, reduces the levels of detergent-insoluble tau, neuronal loss and reverses neurofibrillary tangle-associated brain dysfunction. Thus, compounds that target the cysteine residues of tau may prove useful in halting the progression of Alzheimers disease and other tauopathies.
AB - Neurofibrillary tangles, composed of hyperphosphorylated tau fibrils, are a pathological hallmark of Alzheimers disease; the neurofibrillary tangle load correlates strongly with clinical progression of the disease. A growing body of evidence indicates that tau oligomer formation precedes the appearance of neurofibrillary tangles and contributes to neuronal loss. Here we show that tau oligomer formation can be inhibited by compounds whose chemical backbone includes 1,2-dihydroxybenzene. Specifically, we demonstrate that 1,2-dihydroxybenzene-containing compounds bind to and cap cysteine residues of tau and prevent its aggregation by hindering interactions between tau molecules. Further, we show that orally administered DL-isoproterenol, an adrenergic receptor agonist whose skeleton includes 1,2-dihydroxybenzene and which penetrates the brain, reduces the levels of detergent-insoluble tau, neuronal loss and reverses neurofibrillary tangle-associated brain dysfunction. Thus, compounds that target the cysteine residues of tau may prove useful in halting the progression of Alzheimers disease and other tauopathies.
UR - http://www.scopus.com/inward/record.url?scp=84951843847&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951843847&partnerID=8YFLogxK
U2 - 10.1038/ncomms10216
DO - 10.1038/ncomms10216
M3 - Article
C2 - 26671725
AN - SCOPUS:84951843847
SN - 2041-1723
VL - 6
JO - Nature Communications
JF - Nature Communications
M1 - 10216
ER -